TERAPIA CAR-T EN NEOPLASIAS HEMATOLÓGICAS: AVANCES, TOXICIDADES Y PERSPECTIVAS FUTURAS
DOI:
https://doi.org/10.56238/levv17n62-020Palabras clave:
Terapia CAR-T, Neoplasias Hematológicas, Inmunoterapia, Toxicidad, Recaída TumoralResumen
Las neoplasias hematológicas constituyen un grupo heterogéneo de enfermedades malignas originadas a partir de células del sistema hematopoyético y linfático, incluyendo leucemias, linfomas y mieloma múltiple. A pesar de los avances obtenidos con quimioterapia, radioterapia, anticuerpos monoclonales, inhibidores dirigidos y trasplante de células madre hematopoyéticas, los pacientes con enfermedad recidivante o refractaria aún presentan pronóstico desfavorable y opciones terapéuticas limitadas. En este contexto, la terapia con células T portadoras de receptor quimérico de antígeno, conocida como terapia CAR-T, surgió como una de las principales innovaciones de la inmunoterapia oncológica contemporánea. Este estudio tiene como objetivo analizar, mediante una revisión integradora de la literatura, los avances clínicos, las principales toxicidades y las perspectivas futuras de la terapia CAR-T en el tratamiento de las neoplasias hematológicas. Se trata de una revisión integradora, de enfoque cualitativo y carácter exploratorio, basada en el análisis de publicaciones científicas seleccionadas entre 2017 y 2026, organizadas a partir de un corpus inicial reunido por los autores y complementadas por una búsqueda bibliográfica dirigida. La síntesis de la literatura demuestra que la terapia CAR-T presenta resultados expresivos en neoplasias de células B y en mieloma múltiple, especialmente mediante los objetivos CD19 y BCMA. Sin embargo, su aplicación clínica sigue limitada por toxicidades como síndrome de liberación de citocinas, neurotoxicidad asociada a células efectoras inmunes, citopenias, infecciones, además de desafíos relacionados con recaída tumoral, escape antigénico, alto costo, manufactura individualizada y acceso restringido. Se concluye que la terapia CAR-T representa un cambio de paradigma en la oncohematología, pero su consolidación depende del perfeccionamiento de los productos celulares, del manejo precoz de las toxicidades y de la ampliación de estrategias capaces de hacer esta tecnología más segura, duradera y accesible.
Descargas
Referencias
ALCÂNTARA, Flávia Aparecida Quiel et al. Terapia com células T do receptor de antígeno quimérico (CAR) no tratamento da leucemia linfóide aguda de células B. Interference Journal, v. 11, n. 2, p. 3249-3267, 2025. DOI: 10.36557/2009-3578.2025v11n2p3249-3267. DOI: https://doi.org/10.36557/2009-3578.2025v11n2p3249-3267
ALI, Alaa; DIPERSIO, John F. ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights. Frontiers in Immunology, v. 15, p. 1432799, 2024. DOI: 10.3389/fimmu.2024.1432799. DOI: https://doi.org/10.3389/fimmu.2024.1432799
BANGOLO, Ayrton et al. Comprehensive review of early and late toxicities in CAR T-cell therapy and bispecific antibody treatments for hematologic malignancies. Cancers, v. 17, n. 2, p. 282, 2025. DOI: 10.3390/cancers17020282. DOI: https://doi.org/10.3390/cancers17020282
BHAT, A. A. et al. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. Journal of Translational Medicine, v. 21, art. 449, 2023. DOI: 10.1186/s12967-023-04292-3. DOI: https://doi.org/10.1186/s12967-023-04404-z
ELIAS, Guilherme dos Santos. Novas estratégias em imunoterapia com células CAR-T em pacientes com leucemia linfoblástica aguda: investigando a ascensão da terapêutica. Revista Brasileira de Cancerologia, v. 71, n. 3, e-165017, 2025. DOI: 10.32635/2176-9745.RBC.2025v71n3.5017. DOI: https://doi.org/10.32635/2176-9745.RBC.2025v71n3.5017
HUANG, Huageng et al. Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress. Journal of Hematology & Oncology, v. 17, art. 120, 2024. DOI: 10.1186/s13045-024-01639-1. DOI: https://doi.org/10.1186/s13045-024-01639-1
HUSODHO, Gabriela Valencia Putri et al. Exploring current evidence on bispecific CAR-T cell therapy for acute leukemias: a systematic review. Frontiers in Oncology, v. 16, art. 1720483, 2026. DOI: 10.3389/fonc.2026.1720483. DOI: https://doi.org/10.3389/fonc.2026.1720483
INSTITUTO NACIONAL DE CÂNCER. Estimativa 2026-2028: incidência de câncer no Brasil. Rio de Janeiro: INCA, 2026.
KHAN, Aalia N.; ASIJA, Sweety; PENDHARI, Juber; PURWAR, Rahul. CAR-T cell therapy in hematological malignancies: where are we now and where are we heading for? European Journal of Haematology, v. 112, p. 6-18, 2024. DOI: 10.1111/ejh.14076. DOI: https://doi.org/10.1111/ejh.14076
KONG, Yaojie et al. CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity. Frontiers in Immunology, v. 15, art. 1519671, 2025. DOI: 10.3389/fimmu.2024.1519671. DOI: https://doi.org/10.3389/fimmu.2024.1519671
LEE, Daniel W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biology of Blood and Marrow Transplantation, v. 25, n. 4, p. 625-638, 2019. DOI: 10.1016/j.bbmt.2018.12.758. DOI: https://doi.org/10.1016/j.bbmt.2018.12.758
LOOK, Thomas et al. CAR T cells, CAR NK cells, and CAR macrophages exhibit distinct traits in glioma models but are similarly enhanced when combined with cytokines. Cell Reports Medicine, v. 6, art. 101931, 2025. DOI: 10.1016/j.xcrm.2025.101931. DOI: https://doi.org/10.1016/j.xcrm.2025.101931
LU, Hui et al. From CAR-T cells to CAR-NK cells: a developing immunotherapy method for hematological malignancies. Frontiers in Oncology, v. 11, art. 720501, 2021. DOI: 10.3389/fonc.2021.720501. DOI: https://doi.org/10.3389/fonc.2021.720501
MAUDE, Shannon L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. The New England Journal of Medicine, v. 378, p. 439-448, 2018. DOI: 10.1056/NEJMoa1709866. DOI: https://doi.org/10.1056/NEJMoa1709866
MONTAGNA, Erik et al. CD19 CAR T cells for B cell malignancies: a systematic review and meta-analysis focused on clinical impacts of CAR structural domains, manufacturing conditions, cellular product, doses, patient's age, and tumor types. BMC Cancer, v. 24, art. 1037, 2024. DOI: 10.1186/s12885-024-12651-6. DOI: https://doi.org/10.1186/s12885-024-12651-6
MUNSHI, Nikhil C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. The New England Journal of Medicine, v. 384, n. 8, p. 705-716, 2021. DOI: 10.1056/NEJMoa2024850. DOI: https://doi.org/10.1056/NEJMoa2024850
PAGE, Matthew J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, v. 372, n. 71, 2021. DOI: 10.1136/bmj.n71. DOI: https://doi.org/10.1136/bmj.n71
PASQUI, Daniel M. et al. CAR-T cell therapy for patients with hematological malignancies: a systematic review. European Journal of Haematology, v. 109, n. 6, p. 601-618, 2022. DOI: 10.1111/ejh.13851. DOI: https://doi.org/10.1111/ejh.13851
POSA, Mahesh Kumar et al. CAR T-cell therapy: a promising novel approach for treatment of cancer. Cancer Treatment and Research Communications, v. 47, art. 101125, 2026. DOI: 10.1016/j.ctarc.2026.101125. DOI: https://doi.org/10.1016/j.ctarc.2026.101125
PULSIPHER, Michael A. et al. Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia. Blood Cancer Discovery, v. 3, n. 1, p. 66-81, 2022. DOI: 10.1158/2643-3230.BCD-21-0095. DOI: https://doi.org/10.1158/2643-3230.BCD-21-0095
SOARES, José Eduardo Palacio et al. Terapia com células CAR-T: reprogramação celular para o combate de neoplasias malignas. Revista Médica de Minas Gerais, v. 32, e32210, 2022. DOI: 10.5935/2238-3182.2022e32210. DOI: https://doi.org/10.5935/2238-3182.2022e32210
TOMASIK, Jaromir; JASIŃSKI, Marcin; BASAK, Grzegorz W. Next generations of CAR-T cells: new therapeutic opportunities in hematology? Frontiers in Immunology, v. 13, art. 1034707, 2022. DOI: 10.3389/fimmu.2022.1034707. DOI: https://doi.org/10.3389/fimmu.2022.1034707
VOORDECKERS, Luana Barreto et al. Imunoterapia com células CAR-T como nova perspectiva de tratamento das neoplasias hematológicas. Brazilian Journal of Health Review, v. 7, n. 1, p. 2666-2678, 2024. DOI: 10.34119/bjhrv7n1-215. DOI: https://doi.org/10.34119/bjhrv7n1-215
WANG, Chao et al. CAR-T cell therapy for hematological malignancies: history, status and promise. Heliyon, v. 9, e21776, 2023. DOI: 10.1016/j.heliyon.2023.e21776. DOI: https://doi.org/10.1016/j.heliyon.2023.e21776
WHITTEMORE, Robin; KNAFL, Kathleen. The integrative review: updated methodology. Journal of Advanced Nursing, v. 52, n. 5, p. 546-553, 2005. DOI: 10.1111/j.1365-2648.2005.03621.x. DOI: https://doi.org/10.1111/j.1365-2648.2005.03621.x
WU, Huichao et al. CAR-T and CAR-NK cell therapies in AML: breaking barriers and charting the future. Journal of Translational Medicine, v. 23, art. 1163, 2025. DOI: 10.1186/s12967-025-07151-5. DOI: https://doi.org/10.1186/s12967-025-07151-5
XU, Han et al. Clinical efficacy and safety of combined anti-BCMA and anti-CD19 CAR-T cell therapy for relapsed/refractory multiple myeloma: a systematic review and meta-analysis. Frontiers in Oncology, v. 14, art. 1355643, 2024. DOI: 10.3389/fonc.2024.1355643. DOI: https://doi.org/10.3389/fonc.2024.1355643
ZHANG, Xiaomin et al. CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Frontiers in Immunology, v. 13, art. 927153, 2022. DOI: 10.3389/fimmu.2022.927153. DOI: https://doi.org/10.3389/fimmu.2022.927153
ZUGASTI, Inés et al. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduction and Targeted Therapy, v. 10, art. 210, 2025. DOI: 10.1038/s41392-025-02269-w. DOI: https://doi.org/10.1038/s41392-025-02269-w